Predictors of early discontinuation of dual-antiplatelet therapy: Room for improvement

Circulation

Volumn 122, Issue 10, 2010, Pages 946-948

  Jarvie, Jennifer L ^a   Foody, Joanne M ^b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adherence; antiplatelet; clopidogrel; Editorials

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; ARTERY DISEASE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR RISK; DRUG ELUTING STENT; DRUG WITHDRAWAL; EDITORIAL; HUMAN; KIDNEY DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RESTENOSIS; STENT THROMBOSIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION; NOTE; PREDICTION AND FORECASTING; RISK FACTOR; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; THROMBOSIS;

EID: 77957267963     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.972737     Document Type: Editorial

References (20)

1. Morice MC, Serruys PW, Sousa E, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized comparison of sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346:1773-1780.
2. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Shiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group. Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
3. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herman JP, Van der Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM; TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353-1363.
4. Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, van Domburg RT, Serruys PW; International Cardiologists of the Thoraxcenter (2000 to 2005). The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv. 2009;2:534-541.
5. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLargo A, Wilmer C, Topol EJ; CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Snangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
7. Kushner FG, Hand M, Smith SC Jr, King SB III, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating for 2004 guideline and 2007 Focused Update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009;120:2271-2306.
8. Ho PM, Fihn SD, Wang L, Bryson CL, Lowy E, Maynard C, Magid DJ, Peterson ED, Jesse RL, Rumsfeld JS. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J. 2007;154:846-851.
9. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-2809.
10. Daemen J, Wanaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-678.
11. Ferreira-González I, Marsal JR, Ribera A, Permanyer-Miralda G, García-Del Blanco B, MartÍ G, Cascant P, Martin-Yuste V, Brugaletta S, Sabaté M, Alfonso F, Capote ML, De La Torre JM, Ruíz-Lera M, Simmiguel D, Cárdenas M, Pujol B, Baz JA, Iñiguez A, Trillo R, González-Béjar O, Casanova J, Sánchez-Gila J, García-Dorado D. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation. 2010;122:1017-1025.
12. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772-779.
13. Sheehy O, LeLorier J, Rinfret S. Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ. 2008;178: 413-420.
14. Jackevicius CA, Tu JV, Demers V, Melo M, Cox J, Rinfret S, Kalavrou-ziotis D, Johansen H, Behlouli H, Newman A, Pilote L. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med. 2008;359:1802-1810.
15. Ho PM, Tsai TT, Maddox TM, Powers DJ, Carroll NM, Jackevicius C, Go AS, Margolis KL, DeFor TA, Rumsfeld JS, Magid DJ. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovas Qual Outcomes. 2010;3:261-266.
16. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029.
17. Garavalia L, Ho PM, Garavalia B, Foody JM, Kruse H, Spertus JA, Decker C. Clinician-patient discord: Exploring differences in perspective for discontinuing clopidogrel. Eur J Cardiovasc Nurs. May 21, 2010. DOI: 10.1016/j.ejcnurse.2010.04.002. Available at: http://www. sciencedirect.com/ science?-ob=ArticleURL&-udi = B6X1V-504CNHP-1&-user= 10&-coverDate = 05%2F21%2F2010&-rdoc= 17&-fmt = high&-orig = browse&-srch = doc-info(%23toc%237252%239999% 23999999999%2399999%23FLA%23display%23Articles) &-cdi = 7252&-sort=d&-docanchor=&-ct=30&-acct= C000050221&-version= 1&-urlVersion=0&-userid=10&md5= b304ac50f7ebbe1b1ed81417977326e4. Accessed July 7, 2010.
18. Tsai TT, Ho PM, Xu S, Powers D, Carroll NM, Shetterly SM, Maddox TM, Rumsfeld JS, Margolis K, Go AS, Magid DJ. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: Insights from the HMO Research Network-Stent Registry (HMORN-stent). Circ Cardiovasc Interv. 2010;3:230-235.
19. Decker C, Ahmad H, Moreng KL, Maddox TM, Reid KJ, Jones PG, Spertus JA. Risk factor management after myocardial infarction: reported adherence and outcomes. Am Heart J. 2009;157:556-562.
20. Quality initiatives for hospitalized patient care. Society of Hospital Medicine Web site. http://www.hospitalmedicine.org/AM/Template.cfm? Section = Quality-Improvement. Accessed July 11, 2010.